Trial Profile
A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) With Radiation in Patients With Metastatic Sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Glycopyranosyl lipid adjuvant (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 05 Apr 2017 Results assessing effect of intratumoral injection of G100 on systemic anti-tumor immune response in the soft tissue sarcoma microenvironment, presented at the 108th Annual Meeting of the American Association for Cancer Research.